Solara Active Pharma Sciences Revises Corporate Policies in Line with SEBI Regulations

1 min read     Updated on 06 Feb 2026, 02:37 PM
scanx
Reviewed by
Riya DScanX News Team
Overview

Solara Active Pharma Sciences Limited's Board of Directors approved revisions to two key corporate policies on February 06, 2026. The company amended its Policy for Determining Materiality of Events/Information for Disclosure to align with SEBI Regulation 30 amendments and revised its Policy for Governance of Related Party Transactions in compliance with SEBI Regulation 23 changes. Both updated policies are available on the company's website, demonstrating continued commitment to regulatory compliance and corporate governance standards.

31914473

*this image is generated using AI for illustrative purposes only.

Solara Active Pharma Sciences Limited has announced revisions to its key corporate policies following a Board of Directors meeting held on February 06, 2026. The pharmaceutical company updated two critical governance policies to ensure compliance with recent amendments to SEBI regulations.

Policy Amendments Approved

The board considered and approved amendments to two important corporate policies during their meeting. These revisions demonstrate the company's commitment to maintaining robust governance standards and regulatory compliance.

Policy Updated Regulatory Compliance Availability
Policy for Determining Materiality of Events/Information for Disclosure SEBI Regulation 30 amendments Company website
Policy for Governance of Related Party Transactions SEBI Regulation 23 amendments Company website

Materiality Disclosure Policy Update

The company amended its "Policy for Determining Materiality of Events/Information for Disclosure to Stock Exchanges" to align with recent amendments in Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015. This policy governs how the company determines which events and information require disclosure to stock exchanges, ensuring transparency for investors and market participants.

Related Party Transaction Policy Revision

The Board members reviewed and adopted the revised "Policy for Governance of Related Party Transactions" in compliance with amendments to Regulation 23 of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015. This policy framework ensures proper governance and transparency in transactions between the company and its related parties.

Policy Accessibility

Both amended policies are now available on the company's website at solara.co.in/investor-relations/policies-and-guidelines/, providing stakeholders with easy access to the updated governance frameworks. The company secretary and compliance officer, Pooja Jaya Kumar, signed the regulatory filing confirming these policy updates.

These policy revisions reflect Solara Active Pharma Sciences' ongoing commitment to maintaining high standards of corporate governance and ensuring full compliance with evolving regulatory requirements in the Indian securities market.

Historical Stock Returns for Solara Active Pharma Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.46%+2.84%-6.70%-32.82%-20.09%-61.49%
Solara Active Pharma Sciences
View Company Insights
View All News
like18
dislike

Veritas Finance Limited Reports Strong Q3FY26 Financial Results

2 min read     Updated on 05 Feb 2026, 06:57 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Veritas Finance Limited reported strong Q3FY26 results with total income from operations of ₹46,182.77 lakhs and net profit after tax of ₹8,175.59 lakhs for the quarter ended December 31, 2025. The nine-month performance showed total income of ₹1,33,042.89 lakhs with net profit after tax of ₹21,106.08 lakhs. The NBFC maintains a debt equity ratio of 2.20 and continues its focus on serving micro and small enterprises with various credit solutions.

31843664

*this image is generated using AI for illustrative purposes only.

Veritas Finance Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating strong operational performance across key financial metrics. The Chennai-based non-banking financial company (NBFC) reported robust growth in both revenue and profitability during the third quarter of fiscal year 2026.

Financial Performance Highlights

The company's financial results showcase consistent growth momentum with total income from operations reaching significant levels during the reporting period.

Metric Q3FY26 (Dec 31, 2025) Q2FY26 (Sep 30, 2025) Q3FY25 (Dec 31, 2024)
Total Income from Operations ₹46,182.77 lakhs ₹43,889.75 lakhs ₹39,970.94 lakhs
Net Profit Before Tax ₹10,856.54 lakhs ₹8,848.46 lakhs ₹9,064.96 lakhs
Net Profit After Tax ₹8,175.59 lakhs ₹6,785.44 lakhs ₹6,893.00 lakhs
Total Comprehensive Income ₹7,901.47 lakhs ₹6,785.45 lakhs ₹6,873.88 lakhs

Nine-Month Performance

For the nine-month period ended December 31, 2025, Veritas Finance demonstrated sustained growth across all major financial parameters.

Parameter Nine Months FY26 Nine Months FY25
Total Income from Operations ₹1,33,042.89 lakhs ₹1,11,856.41 lakhs
Net Profit Before Tax ₹27,859.88 lakhs ₹26,785.22 lakhs
Net Profit After Tax ₹21,106.08 lakhs ₹20,204.06 lakhs
Total Comprehensive Income ₹20,697.20 lakhs ₹20,022.90 lakhs

Capital Structure and Key Ratios

The company maintains a stable capital structure with paid-up equity share capital of ₹13,136.42 lakhs as of December 31, 2025. Net worth stood at ₹3,00,448.02 lakhs, while total capital and outstanding debt reached ₹6,59,604.19 lakhs. The debt equity ratio was recorded at 2.20 for the quarter.

Earnings Per Share Performance

Veritas Finance reported earnings per share of ₹6.23 for the quarter ended December 31, 2025, compared to ₹5.15 in the previous quarter and ₹5.25 in the corresponding quarter of the previous year. For the nine-month period, EPS reached ₹16.08.

Business Operations

Veritas Finance Limited operates as an NBFC registered with the Reserve Bank of India and is classified under the middle layer as per scale-based regulations. The company focuses on extending credit to micro and small enterprises, self-employed businesses, and the salaried segment for business expansion, working capital, house construction, and purchase of used commercial vehicles. The company's debt securities are listed on both BSE and NSE.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) 34 for interim financial reporting and have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 4, 2026. The results have also been subjected to limited review by the company's statutory auditors.

Historical Stock Returns for Solara Active Pharma Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.46%+2.84%-6.70%-32.82%-20.09%-61.49%
Solara Active Pharma Sciences
View Company Insights
View All News
like17
dislike

More News on Solara Active Pharma Sciences

1 Year Returns:-20.09%